logo BDSP

Base documentaire

  1. Secondary analysis of economic data : a review of cost-benefit studies of neonatal screening for phenylketonuria.

    Article - En anglais

    Study objective-To estimate the net financial benefit of neonatal screening for phenylketonuria (PKU) : by a simple pooling of cost data from the literature ; and by a more complex modelling approach.

    Design-A systematic literature review was conducted to identify papers containing data on the monetary costs and benefits of neonatal screening for PKU.

    The methodological quality of the studies was appraised, and data were extracted on resource use and expenditure.

    Monetary data were converted to common currency units, and standardised to UK incidence rates.

    Net benefits were calculated for median, best case and worst case scenarios, and the effect of excluding poor quality studies and data was tested.

    The net benefit was also estimated from a model based on data from the literature and assumptions appropriate for the current UK situation.

    Extensive sensitivity analysis was conducted.

    Main results-The direct net benefit of screening based on the median costs and benefits from the 13 studies identified was £143 400 per case detected and treated (£39 000 and £241 800 for worst case and best case scenarios respectively).

    The direct net benefit obtained by the modelling approach was lower at £93 400 per case detected and treated.

    Screening remained cost saving under sensitivity analysis, except with low residential care costs (less than £12 300 per annum), or very low incidence rates (less than 1 in 27 000). (...)

    Mots-clés Pascal : Phénylcétonurie, Nouveau né, Homme, Dépistage, Economie santé, Analyse avantage coût, Angleterre, Grande Bretagne, Royaume Uni, Europe, Revue bibliographique, Evaluation, Métabolisme pathologie, Aminoacidopathie, Système nerveux pathologie, Maladie héréditaire, Enzymopathie

    Mots-clés Pascal anglais : Phenylketonuria, Newborn, Human, Medical screening, Health economy, Cost benefit analysis, England, Great Britain, United Kingdom, Europe, Bibliographic review, Evaluation, Metabolic diseases, Aminoacid disorder, Nervous system diseases, Genetic disease, Enzymopathy

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 99-0168565

    Code Inist : 002B22D01. Création : 16/11/1999.